Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species

Reference

• Akaiwa M, Dugal-Tessier J, Mendelsohn BA. (2020) Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives. Chem Pharm Bull (Tokyo) 68:201-211.
   Google Scholar
• Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, Pillow TH, Sadowsky J, Cheung TK, Phung Q, et al. (2017) Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. Cancer Res 77:7027-7037.
   Google Scholar
• Chang HP, Cheung YK, Shah DK. (2021) Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE). J Clin Med 10(6):1332.
   Google Scholar
• Davies B, Morris T. (1993) Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093-5.
   Google Scholar
• Donaghy H. (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8:659-71.
   Google Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 21:778-84.
   Google Scholar
• Gualberto A. (2012) Brentuximab Vedotin (SGN-35), an Antibody-Drug Conjugate for the Treatment of CD30-positive Malignancies. Expert Opin Investig Drugs 21: 205-16.
   Google Scholar
• Gikanga B, Adeniji NS, Patapoff TW, Chih HW, Yi L. (2016) Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific. Bioconjug Chem 27:1040-9.
   Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
   Google Scholar
• Kwakye RA, Kuntworbe N, Ofori-Kwakye K, Osei YA. (2018) Detection, quantification, and investigation of the red blood cell partitioning of cryptolepine hydrochloride. J Pharm Pharmacogn Res 6:260-270.
   Google Scholar
• Li C, Zhang C, Li Z, Samineni D, Lu D, Wang B, Chen SC, Zhang R, Agarwal P, Fine BM, et al. (2020) Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. MAbs 12:1699768.
   Google Scholar
• Lu D, Jin JY, Girish S, Agarwal P, Li D, Prabhu S, Dere RC, Saad OM, Nazzal D, Koppada N, et al. (2015) Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharm Res 32:1907-19.
   Google Scholar
• Lu T, Gibiansky L, Li X, Li C, Shi R, Agarwal P, Hirata J, Miles D, Chanu P, Girish S, et al. (2020) Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 61(12):2905-2914.
   Google Scholar
• Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. (2018) Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel) 7:10.
   Google Scholar
• Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. (2018) Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36:121-135.
   Google Scholar
• Montel-Hagen A, Blanc L, Boyer-Clavel M, Jacquet C, Vidal M, Sitbon M, Taylor N. (2008) The Glut1 and Glut4 glucose transporters are differentially expressed during perinatal and postnatal erythropoiesis. Blood 112(12):4729-38
   Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharma 2016;7:27-31.
   Google Scholar
• Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, et al. (2012) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 13:901-10.
   Google Scholar
• Yip V, Lee MV, Saad OM, Ma S, Khojasteh SC, Shen BQ. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody-Drug Conjugate in Sprague Dawley Rats. (2021) J Clin Med. 10(6):1323
   Google Scholar
• Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005) A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250-4.
   Google Scholar
• Zhang S, Zhou D, Zheng C, Xiong P, Zhu W, Zheng D. (2021) Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol Ther Oncolytics. 21:329-339
   Google Scholar